Viatris Shares Soar 5.84% After Plunge on FDA Inspection Fallout

Viatris (VTRS) shares surged by 5.84% today, marking a significant rebound after the stock price plummeted to a record low earlier in the day, with an intraday decline of 4.35%.

On April 9, 2025, a class action lawsuit was filed against Viatris Inc. and certain senior executives, alleging violations of federal securities laws. The lawsuit claims that Viatris misled investors about the condition of its manufacturing facilities and the impact of a failed FDA inspection at its Indore, India, facility. The company disclosed on February 27, 2025, that the failed inspection would significantly impact its 2025 revenue and earnings. This revelation led to a substantial drop in Viatris' stock price, falling approximately 15% from $11.24 to $9.53 per share. The lawsuit and the financial repercussions of the FDA inspection are major factors influencing Viatris' stock performance.